Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Sanofi and Regeneron's alirocumab Phase III ODYSSEY trials meet primary endpoints Sanofi and Regeneron Pharmaceuticals have reported positive results from two new Phase III ODYSSEY trials, which evaluated alirocumab that was administered every four weeks to patients with hypercholesterolemia. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Novartis reports positive results from Jakavi Phase III trial in patients with polycythemia vera
By PBR Staff Writer
Swiss drug-maker Novartis has reported positive results from its pivotal Phase III clinical trial of Jakavi (ruxolitinib), an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases, to treat patients with polycythemia vera (PV).
News
Alexza begins Phase IIa trial of AZ-002 to treat epilepsy patients
By PBR Staff Writer
US-based Alexza Pharmaceuticals has started a Phase IIa trial of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS).
News

Contract Research

Applied Molecular Transport, Janssen enter research and license deal for IBS therapy
By PBR Staff Writer
US-based Applied Molecular Transport (AMT) has entered into a research collaboration and license agreement with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ), for a potential inflammatory bowel diseases (IBS) therapy.
News
Annette Funicello funds promising neurovascular research
The Annette Funicello Research Fund for Neurological Diseases has partnered with the International Society for Neurovascular Disease (ISNVD) to target the most promising research projects in the field of neurodegenerative disease.
News

Contract Services

RegeneRx, G-treeBNT form joint venture to develop RGN-259 in US
RegeneRx Biopharmaceuticals, announced that it has entered into agreements with G-treeBNT Co., to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the United States.
News
Galmed and Perrigo in manufacturing services agreement for aramchol API production
By PBR Staff Writer
Galmed Pharmaceuticals has entered into a manufacturing services agreement with Perrigo API for the large-scale production of the active pharmaceutical ingredient (API) of Galmed's product candidate, aramchol.
News